WHAT IS CLAIMED IS:

1. A method of preparing a pharmaceutical composition comprising the steps of:

(a-1) wet granulating at least one active ingredient, and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4).

2. The method of claim 1, wherein the method further comprises the step of (b-1) loading the resulting mixture from step (a-4) into a capsule.

3. The method of claim 1, wherein a lubricant is added during step (a-4), and wherein the method further comprises the step of (c-1) tableting the resulting mixture from step (a-4) to form a tablet.

4. The method of claim 3, wherein the method further comprises the step of (c-2) coating the tablet resulting from step (c-1).

5. The method of claim 4, wherein the (c-2) coating step comprises film-coating and enterically coating the tablet resulting from step (c-1).

6. The method of claim 1, wherein the wet granulating step is preceded by step (a-0) dry blending at least one active ingredient, and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, and fillers.

7. The method of claim 1, wherein the active ingredient is a compound of formula (*A*):



(*A*)

or a pharmaceutically acceptable salt thereof; wherein:

R^{f1} is hydrogen, or R^{f1} and R^{f2} together form a bond;

R^{f2} is hydrogen, or R^{f2} forms a bond with either R^{f1} or R^{x};

each of R^{x} and R^{y} independently is hydrogen, fluoro, or an optionally substituted C_{1-6} aliphatic; or R^{x} and R^{y}, taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring; or R^{x} and R^{f2} together form a bond;

G is hydrogen, an optionally substituted aliphatic or Ring **B** when R^{f1} is hydrogen; and G is hydrogen, $-OR^{5}$, $-N(R^{4})_2$, $-SR^{5}$, an optionally substituted aliphatic, or Ring **B** when R^{f1} and R^{f2} together form a bond;

Ring **A** is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;

Ring **B** is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;

Ring **C** is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;

R^{a} is hydrogen, $-C(O)R^{1}$, $-CO_2R^{1}$, $-SO_2R^{1}$, or a C_{1-3} aliphatic having 0-2 substituents independently selected from R^{3} or R^{7};

R^e is hydrogen, $-OR^5$, $-N(R^4)_2$, $-SR^5$, $-NR^4C(O)R^5$, $-NR^4C(O)N(R^4)_2$, $-NR^4CO_2R^6$, $-N(R^4)SO_2R^6$, $-N(R^4)SO_2N(R^4)_2$, or a C_{1-3} aliphatic optionally substituted with R^3 or R^7;

R^1 is C_{1-6} aliphatic or an optionally substituted aryl, heteroaryl, or heterocyclyl group;

each R^3 independently is selected from the group consisting of -halo, -OH, $-O(C_{1-3}$ alkyl), -CN, $-N(R^4)_2$, $-C(O)(C_{1-3}$ alkyl), $-CO_2H$, $-CO_2(C_{1-3}$ alkyl), $-C(O)NH_2$, and $-C(O)NH(C_{1-3}$ alkyl);

each R^4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R^4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;

each R^5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

each R^6 independently is an optionally substituted aliphatic or aryl group;

each R^7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.

8. The method of claim 7, wherein the active ingredient is a compound of formula (*I*):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^a is selected from the group consisting of C_{1-3} aliphatic, C_{1-3} fluoroaliphatic, -R^1, -T-R^1, -R^2, and -T-R^2;

T is a C_{1-3} alkylene chain optionally substituted with fluoro;

R^1 is an optionally substituted aryl, heteroaryl, or heterocyclyl group;

R^2 is selected from the group consisting of halo, -C≡C-R^3, -CH=CH-R^3, -N(R^4)$_2$, and -OR^5;

R^3 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

each R^4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R^4 on the same nitrogen atom, taken together with the nitrogen atom form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;

R^5 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

R^b is selected from the group consisting of fluoro, chloro, -CH_3, -CF_3, -OH, -OCH_3, -OCF_3, -OCH_2CH_3, and -OCH_2CF_3.

9. The method of claim 1, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof.

10. The method of claim 1, wherein the filler is added during step (a-1).

11. The method of claim 1, wherein the filler is added during step (a-4).

12. The method of claim 1, wherein the filler is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, ethyl cellulose, sorbitol, starch, sucrose, calcium phosphate, powdered cellulose, silicified microcrystalline cellulose, and isomalt.

13. The method of claim 1, wherein the surfactant of step (a-1) or step (a-4) is selected from the group consisting of sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, poloxamers, and glyceryl monooleate.

14. The method of claim 1, wherein the binder of step (a-1) or step (a-4) is selected from the group consisting of polyvinylpyrrolidone, ethyl cellulose, maltose sodium alginate, hydroxypropyl methylcellulose, stearic acid, and pregelatinized starch.

15. The method of claim 1, wherein the disintegrant of step (a-1) and/or step (a-4) is selected from the group consisting of colloidal silicon dioxide, powdered cellulose, calcium silicate, crospovidone, calcium alginate, methyl cellulose, chitosan, carboxy methyl cellulose, croscarmellose sodium, carboxymethyl starch, sodium alginate, sodium starch glycolate, and pregelatinized starch.

16. The method of claim 1, wherein the lubricant is selected from the group consisting of talc, magnesium stearate, sodium stearyl fumarate, glyceryl behenate, hydrogenated vegetable oil, zinc stearate, calcium stearate, sucrose stearate, polyvinyl alcohol, and magnesium lauryl sulfate.

17. The method of claim 1, wherein the glidant is selected from the group consisting of silicon dioxide, colloidal silicon dioxide, tribasic calcium phosphate, magnesium stearate, magnesium trisilicate, powdered cellulose, talc, and starch.

18. The method of claim 1, wherein the buffer is selected from the group consisting of sodium bicarbonate, monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, potassium bicarbonate, sodium carbonate, and potassium carbonate.

19. The method of claim 1, wherein the pharmaceutical composition produced after step (a-4) comprises about 1% w/w to about 60% w/w of active ingredient, about 10% w/w to about 80% w/w of buffer, and about 10% w/w to about 80% w/w of filler.

20. The method of claim 19, wherein the pharmaceutical composition comprises about 2% w/w to about 22% w/w of the active ingredient, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof.

21. The method of claim 19, wherein the pharmaceutical composition comprises about 10% w/w to about 60% w/w of the buffer, wherein the buffer is sodium bicarbonate.

22. The method of claim 19, wherein the pharmaceutical composition comprises about 27% w/w to about 53% w/w of the filler, wherein the filler is microcrystalline cellulose.

23. The method of claim 19, wherein the pharmaceutical composition further comprises from about 0% w/w to about 3% w/w of lubricant, wherein the lubricant is sodium stearyl fumarate.

24. The method of claim 19, wherein the pharmaceutical composition produced after step (a-4) further comprises, about 0% w/w to about 5% w/w of surfactant, about 0% w/w to about 20% w/w of binder, and about 0% w/w to about 20% w/w of disintegrant.

25. The method of claim 24, wherein about 30% to about 70% of the total amount of the disintegrant is added during step (a-1) and about 30% to about 70% of the total amount of the disintegrant is added during step (a-4).

26. The method of claim 1, wherein the solvent of step (a-1) is selected from the group consisting of water, ethanol, and acetone.

27. The method of claim 1, wherein the wet granulating step occurs in a high shear granulator.

28. The method of claim 1, wherein the drying step occurs in a fluid bed granulator.

29. A pharmaceutical composition, wherein the pharmaceutical composition is prepared by the method of claim 1.

30. The pharmaceutical composition of claim 29, wherein the active ingredient is a compound of formula (*A*):



(*A*)

or a pharmaceutically acceptable salt thereof; wherein:

R^{f1} is hydrogen, or R^{f1} and R^{f2} together form a bond;

R^{f2} is hydrogen, or R^{f2} forms a bond with either R^{f1} or R^x;

each of R^x and R^y independently is hydrogen, fluoro, or an optionally substituted C_{1-6} aliphatic; or R^x and R^y, taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring; or R^x and R^{f2} together form a bond;

G is hydrogen, an optionally substituted aliphatic or Ring B when R^{f1} is hydrogen; and G is hydrogen, $-OR^5$, $-N(R^4)_2$, $-SR^5$, an optionally substituted aliphatic, or Ring B when R^{f1} and R^{f2} together form a bond;

Ring **A** is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;

Ring **B** is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;

Ring **C** is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;

R^a is hydrogen, $-C(O)R^1$, $-CO_2R^1$, $-SO_2R^1$, or a C_{1-3} aliphatic having 0-2 substituents independently selected from R^3 or R^7;

R^e is hydrogen, $-OR^5$, $-N(R^4)_2$, $-SR^5$, $-NR^4C(O)R^5$, $-NR^4C(O)N(R^4)_2$, $-NR^4CO_2R^6$, $-N(R^4)SO_2R^6$, $-N(R^4)SO_2N(R^4)_2$, or a C_{1-3} aliphatic optionally substituted with R^3 or R^7;

R^1 is C_{1-6} aliphatic or an optionally substituted aryl, heteroaryl, or heterocyclyl group;

each R^3 independently is selected from the group consisting of -halo, -OH, $-O(C_{1-3}$ alkyl), -CN, $-N(R^4)_2$, $-C(O)(C_{1-3}$ alkyl), $-CO_2H$, $-CO_2(C_{1-3}$ alkyl), $-C(O)NH_2$, and $-C(O)NH(C_{1-3}$ alkyl);

each R^4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R^4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;

each R^5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

each R^6 independently is an optionally substituted aliphatic or aryl group;

each R^7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.

31. The pharmaceutical composition of claim 30, wherein the active ingredient is a compound of formula (*I*):



(*I*)

or a pharmaceutically acceptable salt thereof, wherein:

R^a is selected from the group consisting of C_{1-3} aliphatic, C_{1-3} fluoroaliphatic, $-R^1$, $-T-R^1$, $-R^2$, and $-T-R^2$;

T is a C_{1-3} alkylene chain optionally substituted with fluoro;

R^1 is an optionally substituted aryl, heteroaryl, or heterocyclyl group;

R^2 is selected from the group consisting of halo, $-C\equiv C-R^3$, $-CH=CH-R^3$, $-N(R^4)_2$, and $-OR^5$;

R^3 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

each R^4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R^4 on the same nitrogen atom, taken together with the nitrogen atom form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;

R^5 is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;

R^b is selected from the group consisting of fluoro, chloro, $-CH_3$, $-CF_3$, $-OH$, $-OCH_3$, $-OCF_3$, $-OCH_2CH_3$, and $-OCH_2CF_3$.

32. The pharmaceutical composition of claim 31, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof.

33. The pharmaceutical composition of claim 29, wherein the buffer is sodium bicarbonate.

34. The pharmaceutical composition of claim 29, comprising about 1% w/w to about 60% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 10% w/w to about 80% w/w of sodium bicarbonate, about 10% w/w to about 80% w/w of microcrystalline cellulose, about 0% w/w to about 5% w/w of sodium stearyl fumarate, about 0% w/w to about 5% w/w of sodium lauryl sulfate, about 0% w/w to about 20% w/w of polyvinylpyrrolidone, and about 0% w/w to about 20% w/w of croscarmellose sodium.

35. The pharmaceutical composition of claim 29, comprising about 13.6% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 30.0% w/w of sodium bicarbonate, and about 40.4% w/w of microcrystalline cellulose, about 1.0% w/w of sodium stearyl fumarate, about 2.0% w/w of sodium lauryl sulfate, about 5.0% w/w of polyvinylpyrrolidone, and about 8.0% w/w of croscarmellose sodium.

36. The pharmaceutical composition of claim 35, wherein the pharmaceutical composition is a solid oral pharmaceutical dosage form.

37. The pharmaceutical composition of claim 36, wherein the solid oral pharmaceutical dosage form is a tablet.

38. A pharmaceutical composition comprising about 1% w/w to about 60% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 10% w/w to about 80% w/w of sodium bicarbonate, about 10% w/w to about 80% w/w of microcrystalline cellulose, about 0% w/w to about 5% w/w of sodium stearyl fumarate, about 0% w/w to about 5% w/w of sodium lauryl sulfate, about 0% w/w to about 20% w/w of polyvinylpyrrolidone, about 0% w/w to about 20% w/w of croscarmellose sodium, about 0% w/w to about 10% w/w of film coating, and about 0% w/w to about 20% w/w of enteric coating.

39. A pharmaceutical composition comprising about 1% w/w to about 30% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 30% w/w to about 60% w/w of sodium bicarbonate, and about 20% w/w to about 60% w/w of microcrystalline cellulose, about 1% w/w to about 3% w/w of sodium stearyl fumarate, about 0% w/w to about 3% w/w of sodium lauryl sulfate, about 0% w/w to about 10% w/w of polyvinylpyrrolidone, about 0% w/w to about 15% w/w of croscarmellose sodium, about 0.5 % w/w to about 5.5% w/w of film coating, and about 5% w/w to about 13% w/w of enteric coating.

40. A pharmaceutical composition comprising about 11.9% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 26.1% w/w of sodium bicarbonate, and about 35.1% w/w of microcrystalline cellulose, about 0.9% w/w of sodium stearyl fumarate, about 1.7% w/w of sodium lauryl sulfate, about 4.4% w/w of polyvinylpyrrolidone, about 7.0% w/w of croscarmellose sodium , about 3.6 % w/w of Opadry® clear coating, and about 9.4% w/w of Acryl-EZE® white enteric coating, wherein the total weight includes all the components of the coated tablet including the coatings.

CLAIMS

1. A method of preparing a pharmaceutical composition comprising the steps of:

(a-1) wet granulating at least one active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4).

2. The method of claim **1**, wherein the method further comprises the step of (b-1) loading the resulting mixture from step (a-4) into a capsule.

3. The method of claim **1**, wherein a lubricant is added during step (a-4), and wherein the method further comprises the step of (c-1) tableting the resulting mixture from step (a-4) to form a tablet.

4. The method of claim **3**, wherein the method further comprises the step of (c-2) coating the tablet resulting from step (c-1).

5. The method of claim **4**, wherein the (c-2) coating step comprises film-coating and enterically coating the tablet resulting from step (c-1).

6. The method of claim **1**, wherein the wet granulating step is preceded by step (a-0) dry blending at least one active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, and fillers.

7. The method of claim **1**, wherein the filler is lactose, microcrystalline cellulose, mannitol, ethyl cellulose, sorbitol, starch, sucrose, calcium phosphate, powdered cellulose, silicified microcrystalline cellulose or isomalt.

8. The method of claim **1**, wherein the surfactant of step (a-1) or step (a-4) is sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, poloxamers or glyceryl monooleate.

9. The method of claim **1**, wherein the binder of step (a-1) or step (a-4) is polyvinylpyrrolidone, ethyl cellulose, maltose sodium alginate, hydroxypropyl methylcellulose, stearic acid or pregelatinized starch.

10. The method of claim **1**, wherein the disintegrant of step (a-1) and/or step (a-4) is colloidal silicon dioxide, powdered cellulose, calcium silicate, crospovidone, calcium alginate, methyl cellulose, chitosan, carboxy methyl cellulose, croscarmellose sodium, carboxymethyl starch, sodium alginate, sodium starch glycolate or pregelatinized starch.

11. The method of claim **1**, wherein the lubricant is talc, magnesium stearate, sodium stearyl fumarate, glyceryl behenate, hydrogenated vegetable oil, zinc stearate, calcium stearate, sucrose stearate, polyvinyl alcohol or magnesium lauryl sulfate.

12. The method of claim **1**, wherein the buffer is sodium bicarbonate, monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, potassium bicarbonate, sodium carbonate or potassium carbonate.

13. The method of claim **7**, wherein the filler is microcrystalline cellulose.

14. The method of claim **8**, wherein the surfactant of step (a-1) or step (a-4) is sodium lauryl sulfate.

15. The method of claim **9**, wherein the binder of step (a-1) or step (a-4) is polyvinylpyrrolidone.

16. The method of claim **10**, wherein the disintegrant of step (a-1) and/or step (a-4) is croscarmellose sodium.

17. The method of claim **11**, wherein the lubricant is sodium stearyl fumarate.

18. The method of claim **1**, wherein the solvent of step (a-1) is water, ethanol or acetone.

19. The method of any preceding claim, wherein the buffer is sodium bicarbonate.

20. The method of claim **1**, wherein:
the buffer is sodium bicarbonate;
the filler is microcrystalline cellulose;
the surfactant of step (a-1) or step (a-4) is sodium lauryl sulfate;
the binder of step (a-1) or step (a-4) is polyvinylpyrrolidone;
the disintegrant of step (a-1) and/or step (a-4) is croscarmellose sodium; and
the solvent of step (a-1) is water, ethanol or acetone.

21. A method of preparing a pharmaceutical composition according to claim 1, comprising the steps of:

(a-1) wet granulating an active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-

methoxybenzoic acid, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4);

wherein the composition prepared comprises:

10% w/w to 16% w/w of active ingredient;

20% w/w to 40% w/w of buffer;

35% w/w to 45% w/w of filler;

1% w/w to 2% w/w of surfactant;

3% w/w to 7% w/w of binder;

5% w/w to 10% w/w of disintegrant; and

1% w/w to 2% w/w of lubricant.

22. The method of claim **21**, wherein:

the buffer is sodium bicarbonate, monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, potassium bicarbonate, sodium carbonate or potassium carbonate;

the filler is lactose, microcrystalline cellulose, mannitol, ethyl cellulose, sorbitol, starch, sucrose, calcium phosphate, powdered cellulose, silicified microcrystalline cellulose or isomalt;

the surfactant of step (a-1) or step (a-4) is sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, poloxamers or glyceryl monooleate;

the binder of step (a-1) or step (a-4) is polyvinylpyrrolidone, ethyl cellulose, maltose sodium alginate, hydroxypropyl methylcellulose, stearic acid or pregelatinized starch;

the disintegrant of step (a-1) and/or step (a-4) is colloidal silicon dioxide, powdered cellulose, calcium silicate, crospovidone, calcium alginate, methyl cellulose, chitosan, carboxy methyl cellulose, croscarmellose sodium, carboxymethyl starch, sodium alginate, sodium starch glycolate or pregelatinized starch;

the lubricant is talc, magnesium stearate, sodium stearyl fumarate, glyceryl behenate, hydrogenated vegetable oil, zinc stearate, calcium stearate, sucrose stearate, polyvinyl alcohol or magnesium lauryl sulfate.

23. The method of claim **21**, wherein:

the buffer is sodium bicarbonate;

the filler is microcrystalline cellulose;

the surfactant of step (a-1) or step (a-4) is sodium lauryl sulfate;

the binder of step (a-1) or step (a-4) is polyvinylpyrrolidone;

the disintegrant of step (a-1) and/or step (a-4) is croscarmellose sodium; and

the lubricant is sodium stearyl fumarate.

24. A method of preparing a pharmaceutical composition according to claim 1, comprising the steps of:

(a-1) wet granulating an active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4), and wherein a lubricant is added during step (a-4);

wherein the composition prepared comprises:

10% w/w to 16% w/w of active ingredient;

28% w/w to 40% w/w of buffer, wherein the buffer is sodium bicarbonate;

35% w/w to 45% w/w of filler, wherein the filler is microcrystalline cellulose;

1% w/w to 2% w/w of surfactant, wherein the surfactant is sodium lauryl sulfate;

3% w/w to 7% w/w of binder, wherein the binder is polyvinylpyrrolidone;

5% w/w to 10% w/w of disintegrant, wherein the disintegrant is croscarmellose sodium; and

1% w/w to 2% w/w of lubricant, wherein the lubricant is sodium stearyl fumarate.

25. The method of claim **24**, wherein the method further comprises the step of (c-1) tableting the resulting mixture from step (a-4) to form a tablet.

26. The method of claim **25**, wherein the method further comprises the step of (c-2) coating the tablet resulting from step (c-1).

27. The method of claim **26**, wherein the (c-2) coating step comprises film-coating and enterically coating the tablet resulting from step (c-1).

28. The method of any preceding claim, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof.

29. The method of claim **28**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate monohydrate.

30. A pharmaceutical composition prepared by the method of any of the preceding claims.

31. A pharmaceutical composition prepared by a method comprising the steps of:

(a-1) wet granulating an active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4);

wherein the composition comprises:

10% w/w to 16% w/w of active ingredient;

20% w/w to 40% w/w of buffer;

35% w/w to 45% w/w of filler;

1% w/w to 2% w/w of surfactant;

3% w/w to 7% w/w of binder;

5% w/w to 10% w/w of disintegrant; and

1% w/w to 2% w/w of lubricant.

32. A pharmaceutical composition according to claim 31, prepared by a method comprising the steps of:

(a-1) wet granulating an active ingredient that is the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;

(a-2) drying the wet mixture from step (a-1), to form dried granules;

(a-3) milling the dried granules from step (a-2), to form milled granules; and

(a-4) blending the milled granules from step (a-3) with a buffer and one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;

wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4), and wherein a lubricant is added during step (a-4);

wherein the composition comprises:

10% w/w to 16% w/w of active ingredient;

28% w/w to 40% w/w of buffer, wherein the buffer is sodium bicarbonate;

35% w/w to 45% w/w of filler, wherein the filler is microcrystalline cellulose;

1% w/w to 2% w/w of surfactant, wherein the surfactant is sodium lauryl sulfate;

3% w/w to 7% w/w of binder, wherein the binder is polyvinylpyrrolidone;

5% w/w to 10% w/w of disintegrant, wherein the disintegrant is croscarmellose sodium; and

1% w/w to 2% w/w of lubricant, wherein the lubricant is sodium stearyl fumarate.

33. The pharmaceutical composition of claim **31**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.

34. The pharmaceutical composition of claim **32**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.

35. The pharmaceutical composition of claim **31**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate monohydrate.

36. The pharmaceutical composition of claim **32**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate monohydrate.

37. A pharmaceutical composition comprising as active ingredient the compound 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof, or a crystalline form thereof; and a buffer; wherein the active ingredient is in granular form, and the buffer is extragranular to the active ingredient.

38. The pharmaceutical composition of claim **37**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof.

39. The pharmaceutical composition of claim **38**, wherein the active ingredient is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate monohydrate.

40. The pharmaceutical composition of any one of claims **37-39**, comprising 20% w/w to 40% w/w of sodium bicarbonate buffer.

41. The pharmaceutical composition of any one of claims **37-39**, comprising 10% w/w to 16% w/w of active ingredient, 28% w/w to 40% w/w of buffer, 35% w/w to 45% w/w of filler, 1% w/w to 2% w/w of lubricant, 1% w/w to 2% w/w of surfactant, 3% w/w to 7% w/w of binder, and 5% w/w to 10% w/w of disintegrant.

42. The pharmaceutical composition of claim **41**, wherein the buffer is sodium bicarbonate, monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, potassium bicarbonate, sodium carbonate or potassium carbonate.

43. The pharmaceutical composition of claim **42**, wherein the buffer is sodium bicarbonate.

44. The pharmaceutical composition of claim **41**, wherein the filler is lactose, microcrystalline cellulose, mannitol, ethyl cellulose, sorbitol, starch, sucrose, calcium phosphate, powdered cellulose, silicified microcrystalline cellulose or isomalt.

45. The pharmaceutical composition of claim **44**, wherein the filler is microcrystalline cellulose.

46. The pharmaceutical composition of claim **41**, wherein the surfactant is sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, poloxamers or glyceryl monooleate.

47. The pharmaceutical composition of claim **46**, wherein the surfactant is sodium lauryl sulfate.

48. The pharmaceutical composition of claim **41**, wherein the binder is polyvinylpyrrolidone, ethyl cellulose, maltose sodium alginate, hydroxypropyl methylcellulose, stearic acid or pregelatinized starch.

49. The pharmaceutical composition of claim **48**, wherein the binder is polyvinylpyrrolidone.

50. The pharmaceutical composition of claim **41**, wherein the disintegrant is colloidal silicon dioxide, powdered cellulose, calcium silicate, crospovidone, calcium alginate, methyl cellulose, chitosan, carboxy methyl cellulose, croscarmellose sodium, carboxymethyl starch, sodium alginate, sodium starch glycolate or pregelatinized starch.

51. The pharmaceutical composition of claim **50**, wherein the disintegrant is croscarmellose sodium.

52. The pharmaceutical composition of claim **41**, wherein the lubricant is talc, magnesium stearate, sodium stearyl fumarate, glyceryl behenate, hydrogenated vegetable oil, zinc stearate, calcium stearate, sucrose stearate, polyvinyl alcohol or magnesium lauryl sulfate.

53. The pharmaceutical composition of claim **52**, wherein the lubricant is sodium stearyl fumarate.

54. The pharmaceutical composition of any of claims **37-39**, comprising about 10% w/w to about 16% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, as active ingredient, about 28% w/w to about 40% w/w of sodium bicarbonate as buffer, about 35% w/w to about 45% w/w of microcrystalline cellulose, about 1% w/w to about 2% w/w of sodium stearyl fumarate, about 1% w/w to about 2% w/w of sodium lauryl sulfate, about 3% w/w to about 7% w/w of polyvinylpyrrolidone, and about 5% w/w to about 10% w/w of croscarmellose sodium.

55. A pharmaceutical composition prepared by the method of claim **1**.

56. A pharmaceutical composition prepared by the method of claim **3**.

57. The pharmaceutical composition of claim **55** or **56**, comprising about 13.6% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 30.0% w/w of sodium bicarbonate, and about 40.4% w/w of microcrystalline cellulose, about 1.0% w/w of sodium stearyl fumarate, about 2.0% w/w of sodium lauryl sulfate, about 5.0% w/w of polyvinylpyrrolidone, and about 8.0% w/w of croscarmellose sodium.

58. A pharmaceutical composition prepared by the method of claim **5**.

59. The pharmaceutical composition of claim **58**, comprising about 10% w/w to about 16% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 28% w/w to about 40% w/w of sodium bicarbonate, about 35% w/w to about 45% w/w of microcrystalline cellulose, about 1% w/w to about 2% w/w of sodium stearyl fumarate, about 1% w/w to about 2% w/w of sodium lauryl sulfate, about 3% w/w to about 7% w/w of polyvinylpyrrolidone, about 5% w/w to about 10% w/w of croscarmellose sodium about 2% w/w to about 4% w/w of film coating, and about 7% w/w to about 11% w/w of enteric

coating, wherein the total weight includes all the components of the coated tablet including the coatings.

60. The pharmaceutical composition of claim **58**, comprising about 11.9% w/w of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, about 26.1% w/w of sodium bicarbonate, and about 35.1% w/w of microcrystalline cellulose, about 0.9% w/w of sodium stearyl fumarate, about 1.7% w/w of sodium lauryl sulfate, about 4.4% w/w of polyvinylpyrrolidone, about 7.0% w/w of croscarmellose sodium, about 3.6 % w/w of Opadry® clear coating comprising hydroxyl propyl methylcellulose and PEG, and about 9.4% w/w of Acryl-EZE® white enteric coating comprising methacrylic acid copolymer, wherein the total weight includes all the components of the coated tablet including the coatings.

61. The pharmaceutical composition of any of claims **37-39**, wherein the pharmaceutical composition is in the form of a tablet, wherein the tablet further comprises a film coat and an enteric coat.

62. The tablet of claim **61**, wherein the film coat is present in the amount from 0.5% w/w to 5.5% w/w, and the enteric coat is present in the amount from 5% w/w to 13% w/w.

63. The tablet of claim **61**, wherein the film coat is present in the amount from 1.0% w/w to 5.0% w/w, and the enteric coat is present in the amount from 7% w/w to 11% w/w.